1 5058 145 PHENOTYPIC ALTERATION OF CD8+ T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH EPIGENETIC REPROGRAMMING. IMMUNOSUPPRESSION IS A PREVALENT CLINICAL FEATURE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS, WITH MANY PATIENTS DEMONSTRATING INCREASED SUSCEPTIBILITY TO INFECTIONS AS WELL AS INCREASED FAILURE OF AN ANTITUMOR IMMUNE RESPONSE. HOWEVER, MUCH IS CURRENTLY NOT UNDERSTOOD REGARDING THE PRECISE MECHANISMS THAT ATTRIBUTE TO THIS IMMUNOSUPPRESSIVE PHENOTYPE IN CLL. TO PROVIDE FURTHER CLARITY TO THIS PARTICULAR PHENOMENON, WE ANALYZED THE T-CELL PROFILE OF CLL PATIENT SAMPLES WITHIN A LARGE COHORT AND OBSERVED THAT PATIENTS WITH AN INVERTED CD4/CD8 RATIO HAD A SHORTER TIME TO FIRST TREATMENT AS WELL AS OVERALL SURVIVAL. THESE OBSERVATIONS COINCIDED WITH HIGHER EXPRESSION OF THE IMMUNE CHECKPOINT RECEPTOR PD-1 IN CLL PATIENT CD8+ T CELLS WHEN COMPARED TO AGE-MATCHED HEALTHY DONORS. INTERESTINGLY, WE DISCOVERED THAT INCREASED PD-1 EXPRESSION IN CD8+ T CELLS CORRESPONDS WITH DECREASED DNA METHYLATION LEVELS IN A DISTAL UPSTREAM LOCUS OF THE PD-1 GENE PDCD1. FURTHER ANALYSIS USING LUCIFERASE REPORTER ASSAYS SUGGESTS THAT THE IDENTIFIED PDCD1 DISTAL UPSTREAM REGION ACTS AS AN ENHANCER FOR PDCD1 TRANSCRIPTION AND THIS REGION BECOMES DEMETHYLATED DURING ACTIVATION OF NAIVE CD8+ T CELLS BY ANTI-CD3/ANTI-CD28 ANTIBODIES AND IL2. FINALLY, WE CONDUCTED A GENOME-WIDE DNA METHYLATION ANALYSIS COMPARING CD8+ T CELLS FROM CLL PATIENTS AGAINST HEALTHY DONORS AND IDENTIFIED ADDITIONAL DIFFERENTIALLY METHYLATED GENES WITH KNOWN IMMUNE REGULATORY FUNCTIONS INCLUDING CCR6 AND KLRG1. TAKEN TOGETHER, OUR FINDINGS REVEAL THE OCCURRENCE OF EPIGENETIC REPROGRAMMING TAKING PLACE WITHIN CLL PATIENT CD8+ T CELLS AND HIGHLIGHT THE POTENTIAL MECHANISM OF HOW IMMUNOSUPPRESSION IS ACCOMPLISHED IN CLL. 2016 2 226 33 ACUTE TRANSCRIPTOMIC AND EPIGENETIC ALTERATIONS AT T12 AFTER RAT T10 SPINAL CORD CONTUSIVE INJURY. SPINAL CORD INJURY IS A SEVERELY DEBILITATING CONDITION AFFECTING A SIGNIFICANT POPULATION IN THE USA. SPINAL CORD INJURY PATIENTS OFTEN HAVE INCREASED RISK OF DEVELOPING PERSISTENT NEUROPATHIC PAIN AND OTHER NEURODEGENERATIVE CONDITIONS BEYOND THE PRIMARY LESION CENTER LATER IN THEIR LIFE. THE MOLECULAR MECHANISM CONFERRING TO THE "LATENT" DAMAGES AT DISTAL TISSUES, HOWEVER, REMAINS ELUSIVE. HERE, WE STUDIED MOLECULAR CHANGES CONFERRING ABNORMAL FUNCTIONALITY AT DISTAL SPINAL CORD (T12) BEYOND THE LESION CENTER (T10) BY COMBINING NEXT-GENERATION SEQUENCING (RNA- AND BISULFITE SEQUENCING), SUPER-RESOLUTION MICROSCOPY, AND IMMUNOFLUORESCENCE STAINING AT 7 DAYS POST INJURY. WE OBSERVED SIGNIFICANT TRANSCRIPTOMIC CHANGES PRIMARILY ENRICHED IN NEUROINFLAMMATION AND SYNAPTOGENESIS ASSOCIATED PATHWAYS. TRANSCRIPTION FACTORS (TFS) THAT REGULATE NEUROGENESIS AND NEURON PLASTICITY, INCLUDING EGR1, KLF4, AND MYC, ARE SIGNIFICANTLY UPREGULATED. ALONG WITH GLOBAL CHANGES IN CHROMATIN ARRANGEMENTS AND DNA METHYLATION, INCLUDING 5-METHYLCYTOSINE (5MC) AND 5-HYDROXYMETHYLCYTOSINE (5HMC), BISULFITE SEQUENCING FURTHER REVEALS THE INVOLVEMENT OF DNA METHYLATION CHANGES IN REGULATING CYTOKINE, GROWTH FACTOR, AND ION CHANNEL EXPRESSION. COLLECTIVELY, OUR RESULTS PAVE THE WAY TOWARDS UNDERSTANDING TRANSCRIPTOMIC AND EPIGENOMIC MECHANISM IN CONFERRING LONG-TERM DISEASE RISKS AT DISTAL TISSUES AWAY FROM THE PRIMARY LESION CENTER AND SHED LIGHT ON POTENTIAL MOLECULAR TARGETS THAT GOVERN THE REGULATORY MECHANISM AT DISTAL SPINAL CORD TISSUES. 2023 3 326 34 ALLELIC SILENCING AT THE TUMOR-SUPPRESSOR LOCUS 13Q14.3 SUGGESTS AN EPIGENETIC TUMOR-SUPPRESSOR MECHANISM. GENOMIC MATERIAL FROM CHROMOSOME BAND 13Q14.3 DISTAL TO THE RETINOBLASTOMA LOCUS IS RECURRENTLY LOST IN A VARIETY OF HUMAN NEOPLASMS, INDICATING AN AS-YET-UNIDENTIFIED TUMOR-SUPPRESSOR MECHANISM. NO PATHOGENIC MUTATIONS HAVE BEEN FOUND IN THE MINIMALLY DELETED REGION UNTIL NOW. HOWEVER, IN B CELL CHRONIC LYMPHOCYTIC LEUKEMIA TUMORS WITH LOSS OF ONE COPY OF THE CRITICAL REGION, RESPECTIVE CANDIDATE TUMOR-SUPPRESSOR GENES ARE DOWN-REGULATED BY A FACTOR >2, WHICH WOULD BE EXPECTED BY A NORMAL GENE-DOSAGE EFFECT. THIS FINDING POINTS TO AN EPIGENETIC PATHOMECHANISM. WE FIND THAT THE TWO COPIES OF THE CRITICAL REGION REPLICATE ASYNCHRONOUSLY, SUGGESTING DIFFERENTIAL CHROMATIN PACKAGING OF THE TWO COPIES OF 13Q14.3. ALTHOUGH WE ALSO DETECT MONOALLELIC SILENCING OF GENES LOCALIZED IN THE CRITICAL REGION, MONOALLELIC EXPRESSION ORIGINATES FROM EITHER THE MATERNAL OR PATERNAL COPY, EXCLUDING AN IMPRINTING MECHANISM. DNA METHYLATION ANALYSES REVEALED ONE CPG ISLAND OF THE REGION TO BE METHYLATED. DNA DEMETHYLATION OF THIS CPG ISLAND AND GLOBAL HISTONE HYPERACETYLATION INDUCED BIALLELIC EXPRESSION, WHEREAS REPLICATION TIMING WAS NOT AFFECTED. WE PROPOSE THAT DIFFERENTIAL REPLICATION TIMING REPRESENTS AN EARLY EPIGENETIC MARK THAT DISTINGUISHES THE TWO COPIES OF 13Q14.3, RESULTING IN DIFFERENTIAL CHROMATIN PACKAGING AND MONOALLELIC EXPRESSION. ACCORDINGLY, DELETION OF THE SINGLE ACTIVE COPY OF 13Q14.3 RESULTS IN SIGNIFICANT DOWN-REGULATION OF THE CANDIDATE GENES AND LOSS OF FUNCTION, PROVIDING A MODEL FOR THE INTERACTION OF GENETIC LESIONS AND EPIGENETIC SILENCING AT 13Q14.3 IN B CELL CHRONIC LYMPHOCYTIC LEUKEMIA. 2006 4 5771 40 SPECIFIC MOLECULAR SIGNATURES PREDICT DECITABINE RESPONSE IN CHRONIC MYELOMONOCYTIC LEUKEMIA. MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) ARE CHARACTERIZED BY MUTATIONS IN GENES ENCODING EPIGENETIC MODIFIERS AND ABERRANT DNA METHYLATION. DNA METHYLTRANSFERASE INHIBITORS (DMTIS) ARE USED TO TREAT THESE DISORDERS, BUT RESPONSE IS HIGHLY VARIABLE, WITH FEW MEANS TO PREDICT WHICH PATIENTS WILL BENEFIT. HERE, WE EXAMINED BASELINE DIFFERENCES IN MUTATIONS, DNA METHYLATION, AND GENE EXPRESSION IN 40 CMML PATIENTS WHO WERE RESPONSIVE OR RESISTANT TO DECITABINE (DAC) IN ORDER TO DEVELOP A MOLECULAR MEANS OF PREDICTING RESPONSE AT DIAGNOSIS. WHILE SOMATIC MUTATIONS DID NOT DIFFERENTIATE RESPONDERS FROM NONRESPONDERS, WE IDENTIFIED 167 DIFFERENTIALLY METHYLATED REGIONS (DMRS) OF DNA AT BASELINE THAT DISTINGUISHED RESPONDERS FROM NONRESPONDERS USING NEXT-GENERATION SEQUENCING. THESE DMRS WERE PRIMARILY LOCALIZED TO NONPROMOTER REGIONS AND OVERLAPPED WITH DISTAL REGULATORY ENHANCERS. USING THE METHYLATION PROFILES, WE DEVELOPED AN EPIGENETIC CLASSIFIER THAT ACCURATELY PREDICTED DAC RESPONSE AT THE TIME OF DIAGNOSIS. TRANSCRIPTIONAL ANALYSIS REVEALED DIFFERENCES IN GENE EXPRESSION AT DIAGNOSIS BETWEEN RESPONDERS AND NONRESPONDERS. IN RESPONDERS, THE UPREGULATED GENES INCLUDED THOSE THAT ARE ASSOCIATED WITH THE CELL CYCLE, POTENTIALLY CONTRIBUTING TO EFFECTIVE DAC INCORPORATION. TREATMENT WITH CXCL4 AND CXCL7, WHICH WERE OVEREXPRESSED IN NONRESPONDERS, BLOCKED DAC EFFECTS IN ISOLATED NORMAL CD34+ AND PRIMARY CMML CELLS, SUGGESTING THAT THEIR UPREGULATION CONTRIBUTES TO PRIMARY DAC RESISTANCE. 2015 5 1133 41 COMPREHENSIVE EPIGENOMIC PROFILING OF HUMAN ALVEOLAR EPITHELIAL DIFFERENTIATION IDENTIFIES KEY EPIGENETIC STATES AND TRANSCRIPTION FACTOR CO-REGULATORY NETWORKS FOR MAINTENANCE OF DISTAL LUNG IDENTITY. BACKGROUND: DISRUPTION OF ALVEOLAR EPITHELIAL CELL (AEC) DIFFERENTIATION IS IMPLICATED IN DISTAL LUNG DISEASES SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE, IDIOPATHIC PULMONARY FIBROSIS, AND LUNG ADENOCARCINOMA THAT IMPACT MORBIDITY AND MORTALITY WORLDWIDE. ELUCIDATING UNDERLYING DISEASE PATHOGENESIS REQUIRES A MECHANISTIC MOLECULAR UNDERSTANDING OF AEC DIFFERENTIATION. PREVIOUS STUDIES HAVE FOCUSED ON CHANGES OF INDIVIDUAL TRANSCRIPTION FACTORS, AND TO DATE NO STUDY HAS COMPREHENSIVELY CHARACTERIZED THE DYNAMIC, GLOBAL EPIGENOMIC ALTERATIONS THAT FACILITATE THIS CRITICAL DIFFERENTIATION PROCESS IN HUMANS. RESULTS: WE COMPREHENSIVELY PROFILED THE EPIGENOMIC STATES OF HUMAN AECS DURING TYPE 2 TO TYPE 1-LIKE CELL DIFFERENTIATION, INCLUDING THE METHYLOME AND CHROMATIN FUNCTIONAL DOMAINS, AND INTEGRATED THIS WITH TRANSCRIPTOME-WIDE RNA EXPRESSION DATA. ENHANCER REGIONS WERE DRASTICALLY ALTERED DURING AEC DIFFERENTIATION. TRANSCRIPTION FACTOR BINDING ANALYSIS WITHIN ENHANCER REGIONS REVEALED DIVERSE INTERACTIVE NETWORKS WITH ENRICHMENT FOR MANY TRANSCRIPTION FACTORS, INCLUDING NKX2-1 AND FOXA FAMILY MEMBERS, AS WELL AS TRANSCRIPTION FACTORS WITH LESS WELL CHARACTERIZED ROLES IN AEC DIFFERENTIATION, SUCH AS MEMBERS OF THE MEF2, TEAD, AND AP1 FAMILIES. ADDITIONALLY, ASSOCIATIONS AMONG TRANSCRIPTION FACTORS CHANGED DURING DIFFERENTIATION, IMPLICATING A COMPLEX NETWORK OF HETEROTRIMERIC COMPLEX SWITCHING IN DRIVING DIFFERENTIATION. INTEGRATION OF AEC ENHANCER STATES WITH THE CATALOG OF ENHANCER ELEMENTS IN THE ROADMAP EPIGENOMICS MAPPING CONSORTIUM AND ENCYCLOPEDIA OF DNA ELEMENTS (ENCODE) REVEALED THAT AECS HAVE SIMILAR EPIGENOMIC STRUCTURES TO OTHER PROFILED EPITHELIAL CELL TYPES, INCLUDING HUMAN MAMMARY EPITHELIAL CELLS (HMECS), WITH NKX2-1 SERVING AS A DISTINGUISHING FEATURE OF DISTAL LUNG DIFFERENTIATION. CONCLUSIONS: ENHANCER REGIONS ARE HOTSPOTS OF EPIGENOMIC ALTERATION THAT REGULATE AEC DIFFERENTIATION. FURTHERMORE, THE DIFFERENTIATION PROCESS IS REGULATED BY DYNAMIC NETWORKS OF TRANSCRIPTION FACTORS ACTING IN CONCERT, RATHER THAN INDIVIDUALLY. THESE FINDINGS PROVIDE A ROADMAP FOR UNDERSTANDING THE RELATIONSHIP BETWEEN DISRUPTION OF THE EPIGENETIC STATE DURING AEC DIFFERENTIATION AND DEVELOPMENT OF LUNG DISEASES THAT MAY BE THERAPEUTICALLY AMENABLE. 2021 6 3061 42 GENOME-WIDE DNA METHYLATION ANALYSIS PREDICTS AN EPIGENETIC SWITCH FOR GATA FACTOR EXPRESSION IN ENDOMETRIOSIS. ENDOMETRIOSIS IS A GYNECOLOGICAL DISEASE DEFINED BY THE EXTRAUTERINE GROWTH OF ENDOMETRIAL-LIKE CELLS THAT CAUSE CHRONIC PAIN AND INFERTILITY. THE DISEASE IS LIMITED TO PRIMATES THAT EXHIBIT SPONTANEOUS DECIDUALIZATION, AND DISEASED CELLS ARE CHARACTERIZED BY SIGNIFICANT DEFECTS IN THE STEROID-DEPENDENT GENETIC PATHWAYS THAT TYPIFY THIS PROCESS. ALTERED DNA METHYLATION MAY UNDERLIE THESE DEFECTS, BUT FEW REGIONS WITH DIFFERENTIAL METHYLATION HAVE BEEN IMPLICATED IN THE DISEASE. WE MAPPED GENOME-WIDE DIFFERENCES IN DNA METHYLATION BETWEEN HEALTHY HUMAN ENDOMETRIAL AND ENDOMETRIOTIC STROMAL CELLS AND CORRELATED THIS WITH GENE EXPRESSION USING AN INTERACTION ANALYSIS STRATEGY. WE IDENTIFIED 42,248 DIFFERENTIALLY METHYLATED CPGS IN ENDOMETRIOSIS COMPARED TO HEALTHY CELLS. THESE EXTENSIVE DIFFERENCES WERE NOT UNIDIRECTIONAL, BUT WERE FOCUSED INTRAGENICALLY AND AT SITES DISTAL TO CLASSIC CPG ISLANDS WHERE METHYLATION STATUS WAS TYPICALLY NEGATIVELY CORRELATED WITH GENE EXPRESSION. SIGNIFICANT DIFFERENCES IN METHYLATION WERE MAPPED TO 403 GENES, WHICH INCLUDED A DISPROPORTIONALLY LARGE NUMBER OF TRANSCRIPTION FACTORS. FURTHERMORE, MANY OF THESE GENES ARE IMPLICATED IN THE PATHOLOGY OF ENDOMETRIOSIS AND DECIDUALIZATION. OUR RESULTS TREMENDOUSLY IMPROVE THE SCOPE AND RESOLUTION OF DIFFERENTIAL METHYLATION AFFECTING THE HOX GENE CLUSTERS, NUCLEAR RECEPTOR GENES, AND INTRIGUINGLY THE GATA FAMILY OF TRANSCRIPTION FACTORS. FUNCTIONAL ANALYSIS OF THE GATA FAMILY REVEALED THAT GATA2 REGULATES KEY GENES NECESSARY FOR THE HORMONE-DRIVEN DIFFERENTIATION OF HEALTHY STROMAL CELLS, BUT IS HYPERMETHYLATED AND REPRESSED IN ENDOMETRIOTIC CELLS. GATA6, WHICH IS HYPOMETHYLATED AND ABUNDANT IN ENDOMETRIOTIC CELLS, POTENTLY BLOCKED HORMONE SENSITIVITY, REPRESSED GATA2, AND INDUCED MARKERS OF ENDOMETRIOSIS WHEN EXPRESSED IN HEALTHY ENDOMETRIAL CELLS. THE UNIQUE EPIGENETIC FINGERPRINT IN ENDOMETRIOSIS SUGGESTS DNA METHYLATION IS AN INTEGRAL COMPONENT OF THE DISEASE, AND IDENTIFIES A NOVEL ROLE FOR THE GATA FAMILY AS KEY REGULATORS OF UTERINE PHYSIOLOGY-ABERRANT DNA METHYLATION IN ENDOMETRIOTIC CELLS CORRELATES WITH A SHIFT IN GATA ISOFORM EXPRESSION THAT FACILITATES PROGESTERONE RESISTANCE AND DISEASE PROGRESSION. 2014 7 4617 35 NERVE INJURY-INDUCED CHRONIC PAIN IS ASSOCIATED WITH PERSISTENT DNA METHYLATION REPROGRAMMING IN DORSAL ROOT GANGLION. NERVE INJURY-INDUCED HYPERACTIVITY OF PRIMARY SENSORY NEURONS IN THE DORSAL ROOT GANGLION (DRG) CONTRIBUTES TO CHRONIC PAIN DEVELOPMENT, BUT THE UNDERLYING EPIGENETIC MECHANISMS REMAIN POORLY UNDERSTOOD. HERE WE DETERMINED GENOME-WIDE CHANGES IN DNA METHYLATION IN THE NERVOUS SYSTEM IN NEUROPATHIC PAIN. SPINAL NERVE LIGATION (SNL), BUT NOT PACLITAXEL TREATMENT, IN MALE SPRAGUE DAWLEY RATS INDUCED A CONSISTENT LOW-LEVEL HYPOMETHYLATION IN THE CPG SITES IN THE DRG DURING THE ACUTE AND CHRONIC PHASES OF NEUROPATHIC PAIN. DNA METHYLATION REMODELING IN THE DRG OCCURRED EARLY AFTER SNL AND PERSISTED FOR AT LEAST 3 WEEKS. SNL CAUSED DNA METHYLATION CHANGES AT 8% OF CPG SITES WITH PREVAILING HYPOMETHYLATION OUTSIDE OF CPG ISLANDS, IN INTRONS, INTERGENIC REGIONS, AND REPETITIVE SEQUENCES. IN CONTRAST, SNL CAUSED MORE GAINS OF METHYLATION IN THE SPINAL CORD AND PREFRONTAL CORTEX. THE DNA METHYLATION CHANGES IN THE INJURED DRGS RECAPITULATED DEVELOPMENTAL REPROGRAMMING AT THE NEONATAL STAGE. METHYLATION REPROGRAMMING WAS CORRELATED WITH INCREASED GENE EXPRESSION VARIABILITY. A DIET DEFICIENT IN METHYL DONORS INDUCED HYPOMETHYLATION AND PAIN HYPERSENSITIVITY. INTRATHECAL ADMINISTRATION OF THE DNA METHYLTRANSFERASE INHIBITOR RG108 CAUSED LONG-LASTING PAIN HYPERSENSITIVITY. DNA METHYLATION REPROGRAMMING IN THE DRG THUS CONTRIBUTES TO NERVE INJURY-INDUCED CHRONIC PAIN. RESTORING DNA METHYLATION MAY REPRESENT A NEW THERAPEUTIC APPROACH TO TREAT NEUROPATHIC PAIN.SIGNIFICANCE STATEMENT EPIGENETIC MECHANISMS ARE CRITICALLY INVOLVED IN THE TRANSITION FROM ACUTE TO CHRONIC PAIN AFTER NERVE INJURY. HOWEVER, GENOME-WIDE CHANGES IN DNA METHYLATION IN THE NERVOUS SYSTEM AND THEIR ROLES IN NEUROPATHIC PAIN DEVELOPMENT REMAIN UNCLEAR. HERE WE USED DIGITAL RESTRICTION ENZYME ANALYSIS OF METHYLATION TO QUANTITATIVELY DETERMINE GENOME-WIDE DNA METHYLATION CHANGES CAUSED BY NERVE INJURY. WE SHOWED THAT NERVE INJURY CAUSED DNA METHYLATION CHANGES AT 8% OF CPG SITES WITH PREVAILING HYPOMETHYLATION OUTSIDE OF CPG ISLANDS IN THE DORSAL ROOT GANGLION. REDUCING DNA METHYLATION INDUCED PAIN HYPERSENSITIVITY, WHEREAS INCREASING DNA METHYLATION ATTENUATED NEUROPATHIC PAIN. THESE FINDINGS EXTEND OUR UNDERSTANDING OF THE EPIGENETIC MECHANISM OF CHRONIC NEUROPATHIC PAIN AND SUGGEST NEW STRATEGIES TO TREAT NERVE INJURY-INDUCED CHRONIC PAIN. 2018 8 66 41 A KEY ROLE FOR EZH2 IN EPIGENETIC SILENCING OF HOX GENES IN MANTLE CELL LYMPHOMA. THE CHROMATIN MODIFIER EZH2 IS OVEREXPRESSED AND ASSOCIATED WITH INFERIOR OUTCOME IN MANTLE CELL LYMPHOMA (MCL). RECENTLY, WE DEMONSTRATED PREFERENTIAL DNA METHYLATION OF HOX GENES IN MCL COMPARED WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), DESPITE THESE GENES NOT BEING EXPRESSED IN EITHER ENTITY. SINCE EZH2 HAS BEEN SHOWN TO REGULATE HOX GENE EXPRESSION, TO GAIN FURTHER INSIGHT INTO ITS POSSIBLE ROLE IN DIFFERENTIAL SILENCING OF HOX GENES IN MCL VS. CLL, WE PERFORMED DETAILED EPIGENETIC CHARACTERIZATION USING REPRESENTATIVE CELL LINES AND PRIMARY SAMPLES. WE OBSERVED SIGNIFICANT OVEREXPRESSION OF EZH2 IN MCL VS. CLL. CHROMATIN IMMUNE PRECIPITATION (CHIP) ASSAYS REVEALED THAT EZH2 CATALYZED REPRESSIVE H3 LYSINE 27 TRIMETHYLATION (H3K27ME3), WHICH WAS SUFFICIENT TO SILENCE HOX GENES IN CLL, WHEREAS IN MCL H3K27ME3 IS ACCOMPANIED BY DNA METHYLATION FOR A MORE STABLE REPRESSION. MORE IMPORTANTLY, HYPERMETHYLATION OF THE HOX GENES IN MCL RESULTED FROM EZH2 OVEREXPRESSION AND SUBSEQUENT RECRUITMENT OF THE DNA METHYLATION MACHINERY ONTO HOX GENE PROMOTERS. THE IMPORTANCE OF EZH2 UPREGULATION IN THIS PROCESS WAS FURTHER UNDERSCORED BY SIRNA TRANSFECTION AND EZH2 INHIBITOR EXPERIMENTS. ALTOGETHER, THESE OBSERVATIONS IMPLICATE EZH2 IN THE LONG-TERM SILENCING OF HOX GENES IN MCL, AND ALLUDE TO ITS POTENTIAL AS A THERAPEUTIC TARGET WITH CLINICAL IMPACT. 2013 9 857 34 CHROMATIN ARCHITECTURE REVEALS CELL TYPE-SPECIFIC TARGET GENES FOR KIDNEY DISEASE RISK VARIANTS. BACKGROUND: CELL TYPE-SPECIFIC TRANSCRIPTIONAL PROGRAMMING RESULTS FROM THE COMBINATORIAL INTERPLAY BETWEEN THE REPERTOIRE OF ACTIVE REGULATORY ELEMENTS. DISEASE-ASSOCIATED VARIANTS DISRUPT SUCH PROGRAMMING, LEADING TO ALTERED EXPRESSION OF DOWNSTREAM REGULATED GENES AND THE ONSET OF PATHOLOGICAL STATES. HOWEVER, DUE TO THE NON-LINEAR REGULATORY PROPERTIES OF NON-CODING ELEMENTS SUCH AS ENHANCERS, WHICH CAN ACTIVATE TRANSCRIPTION AT LONG DISTANCES AND IN A NON-DIRECTIONAL WAY, THE IDENTIFICATION OF CAUSAL VARIANTS AND THEIR TARGET GENES REMAINS CHALLENGING. HERE, WE PROVIDE A MULTI-OMICS ANALYSIS TO IDENTIFY REGULATORY ELEMENTS ASSOCIATED WITH FUNCTIONAL KIDNEY DISEASE VARIANTS, AND DOWNSTREAM REGULATED GENES. RESULTS: IN ORDER TO UNDERSTAND THE GENETIC RISK OF KIDNEY DISEASES, WE GENERATED A COMPREHENSIVE DATASET OF THE CHROMATIN LANDSCAPE OF HUMAN KIDNEY TUBULE CELLS, INCLUDING TRANSCRIPTION-CENTERED 3D CHROMATIN ORGANIZATION, HISTONE MODIFICATIONS DISTRIBUTION AND TRANSCRIPTOME WITH HICHIP, CHIP-SEQ AND RNA-SEQ. WE IDENTIFIED GENOME-WIDE FUNCTIONAL ELEMENTS AND THOUSANDS OF INTERACTIONS BETWEEN THE DISTAL ELEMENTS AND TARGET GENES. THE RESULTS REVEALED THAT RISK VARIANTS FOR RENAL TUMOR AND CHRONIC KIDNEY DISEASE WERE ENRICHED IN KIDNEY TUBULE CELLS. WE FURTHER PINPOINTED THE TARGET GENES FOR THE VARIANTS AND VALIDATED TWO TARGET GENES BY CRISPR/CAS9 GENOME EDITING TECHNIQUES IN ZEBRAFISH, DEMONSTRATING THAT SLC34A1 AND MTX1 WERE INDISPENSABLE GENES TO MAINTAIN KIDNEY FUNCTION. CONCLUSIONS: OUR RESULTS PROVIDE A VALUABLE MULTI-OMICS RESOURCE ON THE CHROMATIN LANDSCAPE OF HUMAN KIDNEY TUBULE CELLS AND ESTABLISH A BIOINFORMATIC PIPELINE IN DISSECTING FUNCTIONS OF KIDNEY DISEASE-ASSOCIATED VARIANTS BASED ON CELL TYPE-SPECIFIC EPIGENOME. 2021 10 3459 29 HYPOMETHYLATION OF NERVE GROWTH FACTOR (NGF) PROMOTES BINDING OF C/EBPALPHA AND CONTRIBUTES TO INFLAMMATORY HYPERALGESIA IN RATS. BACKGROUND: CHRONIC PAIN USUALLY ACCOMPANIED BY TISSUE DAMAGE AND INFLAMMATION. HOWEVER, THE PATHOGENESIS OF CHRONIC PAIN REMAINS UNCLEAR. METHODS: WE INVESTIGATED THE ROLE OF NERVE GROWTH FACTOR (NGF) IN CHRONIC INFLAMMATORY PAIN INDUCED BY COMPLETE FREUND'S ADJUVANT (CFA), EXPLORED THE METHYLATION STATUS OF CPG ISLANDS IN THE PROMOTER REGION OF THE NGF GENE, AND CLARIFIED THE FUNCTION AND MECHANISM OF C/EBPALPHA-NGF SIGNALING PATHWAY FROM EPIGENETIC PERSPECTIVE IN THE CHRONIC INFLAMMATORY PAIN MODEL. RESULTS: CFA INDUCED SIGNIFICANT HYPERALGESIA AND CONTINUOUS UPREGULATION OF NGF MRNA AND PROTEIN LEVELS IN THE L4-6 DORSAL ROOT GANGLIONS (DRGS) IN RATS. HYPOMETHYLATION OF CPG ISLANDS OCCURRED IN THE NGF GENE PROMOTER REGION AFTER CFA TREATMENT. AT THE SAME TIME, THE MIR-29B EXPRESSION LEVEL WAS SIGNIFICANTLY INCREASED, WHILE THE DNA METHYLTRANSFERASE 3B (DNMT3B) LEVEL REDUCED SIGNIFICANTLY. MOREOVER, CFA TREATMENT PROMOTED BINDING OF C/EBPALPHA TO THE NGF GENE PROMOTER REGION AND C/EBPALPHA SIRNA TREATMENT OBVIOUSLY DECREASED EXPRESSION OF NGF LEVELS AND ALSO ALLEVIATE INFLAMMATORY HYPERALGESIA SIGNIFICANTLY IN RATS. CONCLUSION: COLLECTIVELY, THE RESULTS INDICATED THAT CFA LEADS TO THE UPREGULATION OF MIR-29B LEVEL, WHICH REPRESSES THE EXPRESSION OF DNMT3B, ENHANCES THE DEMETHYLATION OF THE NGF GENE PROMOTER REGION, AND PROMOTES THE BINDING OF C/EBPALPHA WITH THE NGF GENE PROMOTER, THUS RESULTS IN THE UPREGULATION OF NGF GENE EXPRESSION AND MAINTENANCE OF CHRONIC INFLAMMATORY PAIN. 2020 11 3918 40 LINKING ABERRANT CHROMATIN FEATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA TO TRANSCRIPTION FACTOR NETWORKS. IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), A DIVERSE SET OF GENETIC MUTATIONS IS EMBEDDED IN A DEREGULATED EPIGENETIC LANDSCAPE THAT DRIVES CANCEROGENESIS. TO ELUCIDATE THE ROLE OF ABERRANT CHROMATIN FEATURES, WE MAPPED DNA METHYLATION, SEVEN HISTONE MODIFICATIONS, NUCLEOSOME POSITIONS, CHROMATIN ACCESSIBILITY, BINDING OF EBF1 AND CTCF, AS WELL AS THE TRANSCRIPTOME OF B CELLS FROM CLL PATIENTS AND HEALTHY DONORS. A GLOBALLY INCREASED HISTONE DEACETYLASE ACTIVITY WAS DETECTED AND HALF OF THE GENOME COMPRISED TRANSCRIPTIONALLY DOWNREGULATED PARTIALLY DNA METHYLATED DOMAINS DEMARCATED BY CTCF CLL SAMPLES DISPLAYED A H3K4ME3 REDISTRIBUTION AND NUCLEOSOME GAIN AT PROMOTERS AS WELL AS CHANGES OF ENHANCER ACTIVITY AND ENHANCER LINKAGE TO TARGET GENES. A DNA BINDING MOTIF ANALYSIS IDENTIFIED TRANSCRIPTION FACTORS THAT GAINED OR LOST BINDING IN CLL AT SITES WITH ABERRANT CHROMATIN FEATURES. THESE FINDINGS WERE INTEGRATED INTO A GENE REGULATORY ENHANCER CONTAINING NETWORK ENRICHED FOR B-CELL RECEPTOR SIGNALING PATHWAY COMPONENTS. OUR STUDY PREDICTS NOVEL MOLECULAR LINKS TO TARGETS OF CLL THERAPIES AND PROVIDES A VALUABLE RESOURCE FOR FURTHER STUDIES ON THE EPIGENETIC CONTRIBUTION TO THE DISEASE. 2019 12 1620 34 DNA METHYLTRANSFERASE-MEDIATED TRANSCRIPTIONAL SILENCING IN MALIGNANT GLIOMA: A COMBINED WHOLE-GENOME MICROARRAY AND PROMOTER ARRAY ANALYSIS. EPIGENETIC INACTIVATION OF TUMOR SUPPRESSOR GENES IS A COMMON FEATURE IN HUMAN CANCER. PROMOTER HYPERMETHYLATION AND HISTONE DEACETYLATION ARE REVERSIBLE EPIGENETIC MECHANISMS ASSOCIATED WITH TRANSCRIPTIONAL REGULATION. DNA METHYLTRANSFERASES (DNMT1 AND DNMT3B) REGULATE AND MAINTAIN PROMOTER METHYLATION AND ARE OVEREXPRESSED IN HUMAN CANCER. WE PERFORMED WHOLE-GENOME MICROARRAY ANALYSIS TO IDENTIFY GENES WITH ALTERED EXPRESSION AFTER RNAI-INDUCED SUPPRESSION OF DNMT IN A GLIOBLASTOMA MULTIFORME (GBM) CELL LINE. WE THEN IDENTIFIED GENES WITH BOTH DECREASED EXPRESSION AND EVIDENCE OF PROMOTER CPG ISLAND HYPERMETHYLATION IN GBM TISSUE SAMPLES USING A COMBINED WHOLE-GENOME MICROARRAY TRANSCRIPTOME ANALYSIS IN CONJUNCTION WITH A PROMOTER ARRAY ANALYSIS AFTER DNA IMMUNOPRECIPITATION WITH ANTI-5-METHYLCYTIDINE. DNMT1 AND 3B KNOCKDOWN RESULTED IN THE RESTORED EXPRESSION OF 308 GENES THAT ALSO CONTAINED PROMOTER REGION HYPERMETHYLATION. OF THESE, 43 WERE ALSO FOUND TO BE DOWNREGULATED IN GBM TISSUE SAMPLES. THREE DOWNREGULATED GENES WITH HYPERMETHYLATED PROMOTERS AND RESTORED EXPRESSION IN RESPONSE TO ACUTE DNMT SUPPRESSION WERE ASSAYED FOR METHYLATION CHANGES USING BISULFITE SEQUENCE ANALYSIS OF THE PROMOTER REGION AFTER CHRONIC DNMT SUPPRESSION. RESTORATION OF GENE EXPRESSION WAS NOT ASSOCIATED WITH CHANGES IN PROMOTER REGION METHYLATION, BUT RATHER WITH CHANGES IN HISTONE METHYLATION AND CHROMATIN CONFORMATION. TWO OF THE IDENTIFIED GENES EXHIBITED GROWTH SUPPRESSIVE ACTIVITY IN IN VITRO ASSAYS. COMBINING TARGETED GENETIC MANIPULATIONS WITH COMPREHENSIVE GENOMIC AND EXPRESSION ANALYSES PROVIDES A POTENTIALLY POWERFUL NEW APPROACH FOR IDENTIFYING EPIGENETICALLY REGULATED GENES IN GBM. 2009 13 2078 37 EPIGENETIC DIVERGENCE IN THE TRPA1 PROMOTER CORRELATES WITH PRESSURE PAIN THRESHOLDS IN HEALTHY INDIVIDUALS. THE EXPRESSION PATTERN OF IMPORTANT TRANSDUCTION MOLECULES IN NOCICEPTIVE SENSORY NEURONS IS LIKELY TO DICTATE PAIN SENSITIVITY. WHILE THIS NOTION IS WELL ESTABLISHED FOR INCREASED PAIN SENSITIVITIES UNDER CONDITIONS LIKE INFLAMMATION AND NEUROPATHY, LESS IS KNOWN AS TO WHICH MOLECULES ARE DEFINING INTERINDIVIDUAL DIFFERENCES IN PAIN SENSITIVITY IN HEALTHY SUBJECTS. A GENOME-WIDE METHYLATION ANALYSIS ON MONOZYGOTIC TWINS FOUND THAT METHYLATION OF A CPG DINUCLEOTIDE IN THE PROMOTER OF TRANSIENT RECEPTOR POTENTIAL ANKYRIN 1 (TRPA1) IS INVERSELY ASSOCIATED WITH THE THRESHOLD FOR HEAT-INDUCED PAIN. SEVERAL IN VITRO STUDIES ALSO SUGGEST THAT TRPA1 MEDIATES MECHANICAL SENSITIVITY OF SENSORY AFFERENTS, THUS POTENTIALLY MEDIATING PRESSURE-EVOKED PAIN. IN THE PRESENT STUDY, WE THEREFORE INVESTIGATED THE EPIGENETIC PREDISPOSITION FOR PRESSURE PAIN BY ANALYZING THE METHYLATION STATUS OF 47 CPG SITES IN THE PROMOTER REGION OF TRPA1. USING DNA FROM WHOLE-BLOOD SAMPLES OF 75 HEALTHY VOLUNTEERS, WE FOUND THAT THE SAME CPG SITE PREVIOUSLY FOUND TO AFFECT THE THRESHOLD FOR HEAT-EVOKED PAIN IS HYPERMETHYLATED IN SUBJECTS WITH A LOW THRESHOLD FOR PRESSURE PAIN. WE ALSO FOUND GENDER DIFFERENCES, WITH FEMALES DISPLAYING HIGHER METHYLATION RATES COMBINED WITH HIGHER PRESSURE PAIN SENSITIVITIES AS COMPARED WITH MALES. IN CONCLUSION, OUR FINDINGS SUPPORT THE NOTION THAT EPIGENETIC REGULATION OF TRPA1 SEEMS TO REGULATE THERMAL AND MECHANICAL PAIN SENSITIVITIES. 2017 14 2465 32 EPIGENETIC THERAPY WITH HYDRALAZINE AND MAGNESIUM VALPROATE REVERSES IMATINIB RESISTANCE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA. THE EPIGENETIC DRUGS HYDRALAZINE AND VALPROATE WERE ADMINISTERED IN A COMPASSIONATE MANNER TO 8 PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) REFRACTORY TO IMATINIB. TWO PATIENTS HAD A COMPLETE HEMATOLOGIC RESPONSE (25%),1 MAJOR CYTOGENETIC RESPONSE, 1 COMPLETE CYTOGENETIC RESPONSE (25% ANY CYTOGENETIC RESPONSE), AND 3 (37.5%)STABLE DISEASE. NO GRADE 3 OR 4 TOXICITY WAS OBSERVED. THESE RESULTS SHOW THE ABILITY OF EPIGENETIC THERAPY TO REVERT IMATINIB RESISTANCE. BACKGROUND: EPIGENETIC ALTERATIONS PARTICIPATE IN THE DEVELOPMENT OF ACQUIRED RESISTANCE TO IMATINIB, HENCE, THE DNA METHYLATION, AND HISTONE DEACETYLASE INHIBITORS HYDRALAZINE AND VALPROATE, RESPECTIVELY, HAS THE POTENTIAL TO OVERCOME IT. PATIENT AND METHODS: A SERIES OF 8 PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) REFRACTORY TO IMATINIB MESYLATE WITH NO ACCESS TO SECOND-GENERATION TYROSINE KINASE INHIBITORS WERE TREATED WITH HYDRALAZINE AND VALPROATE IN A COMPASSIONATE MANNER. CLINICAL EFFICACY AND SAFETY OF THESE DRUGS ADDED TO IMATINIB MESYLATE WERE EVALUATED. RESULTS: TWO PATIENTS WERE IN THE BLAST PHASE, 5 WERE IN THE ACCELERATED PHASE, AND 1 WAS IN THE CHRONIC PHASE. ALL THE PATIENTS CONTINUED WITH THE SAME DOSE OF IMATINIB THAT THEY HAD BEEN RECEIVING AT THE TIME OF DEVELOPMENT OF RESISTANCE, WITH A MEDIAN DOSE OF 600 MG DAILY (RANGE, 400-800 MG). THE MEDIAN TIME FROM DIAGNOSIS OF CML TO THE START OF HYDRALAZINE AND VALPROATE WAS 53.6 MONTHS (RANGE, 19-84 MONTHS). TWO (25%) PATIENTS HAD A COMPLETE HEMATOLOGIC RESPONSE, ONE (12.5%) HAD AN MAJOR CYTOGENETIC RESPONSE, AND ONE (12.5%) HAD A COMPLETE CYTOGENETIC RESPONSE. THREE (37.5%) PATIENTS HAD STABLE DISEASE, AND ONLY ONE (12.5%) PATIENT FAILED TO RESPOND. AT A MEDIAN FOLLOW-UP TIME OF 18 MONTHS (RANGE, 3-18 MONTHS), THE MEDIAN SURVIVAL HAD NOT BEEN REACHED, AND THE PROJECTED OVERALL SURVIVAL WAS 63%. ALL THE PATIENTS HAD MILD NEUROLOGIC TOXICITY, INCLUDING DISTAL TREMOR AND SOMNOLENCE. NO GRADE 3 OR 4 TOXICITY WAS OBSERVED. CONCLUSIONS: OUR RESULTS SUGGEST THAT THE EPIGENETIC DRUGS HYDRALAZINE AND VALPROATE REVERT THE RESISTANCE TO IMATINIB IN PATIENTS WITH CML. 2012 15 2398 27 EPIGENETIC REPROGRAMMING OF CORTICAL NEURONS THROUGH ALTERATION OF DOPAMINERGIC CIRCUITS. ALTERATIONS OF THE DOPAMINERGIC SYSTEM ARE ASSOCIATED WITH THE COGNITIVE AND FUNCTIONAL DYSFUNCTIONS THAT CHARACTERIZE COMPLEX NEUROPSYCHIATRIC DISORDERS. WE MODELED A DYSFUNCTIONAL DOPAMINERGIC SYSTEM USING MICE WITH TARGETED ABLATION OF DOPAMINE (DA) D2 AUTORECEPTORS IN MESENCEPHALIC DOPAMINERGIC NEURONS. LOSS OF D2 AUTORECEPTORS ABOLISHES D2-MEDIATED CONTROL OF DA SYNTHESIS AND RELEASE. HERE, WE SHOW THAT THIS MUTATION LEADS TO A PROFOUND ALTERATION OF THE GENOMIC LANDSCAPE OF NEURONS RECEIVING DOPAMINERGIC AFFERENTS AT DISTAL SITES, SPECIFICALLY IN THE PREFRONTAL CORTEX. INDEED, WE OBSERVED A REMARKABLE DOWNREGULATION OF GENE EXPRESSION IN THIS AREA OF ~2000 GENES, WHICH INVOLVES A WIDESPREAD INCREASE IN THE HISTONE REPRESSIVE MARK H3K9ME2/3. THIS REPROGRAMMING PROCESS IS COUPLED TO PSYCHOTIC-LIKE BEHAVIORS IN THE MUTANT MICE. IMPORTANTLY, CHRONIC TREATMENT WITH A DA AGONIST CAN REVERT THE GENOMIC PHENOTYPE. THUS, CORTICAL NEURONS UNDERGO A PROFOUND EPIGENETIC REPROGRAMMING IN RESPONSE TO DYSFUNCTIONAL D2 AUTORECEPTOR SIGNALING LEADING TO ALTERED DA LEVELS, A PROCESS THAT MAY UNDERLIE A NUMBER OF NEUROPSYCHIATRIC DISORDERS. 2014 16 2300 30 EPIGENETIC REGULATION OF BDNF EXPRESSION IN THE PRIMARY SENSORY NEURONS AFTER PERIPHERAL NERVE INJURY: IMPLICATIONS IN THE DEVELOPMENT OF NEUROPATHIC PAIN. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IS KNOWN TO BE UP-REGULATED IN THE DORSAL ROOT GANGLION (DRG) AFTER PERIPHERAL NERVE INJURY, AND TO CONTRIBUTE TO NEUROPATHIC PAIN. HERE, WE FOUND THAT THERMAL HYPERALGESIA AND MECHANICAL ALLODYNIA AT DAY 7 POST-INJURY WERE INHIBITED ONLY WHEN ANTI-BDNF ANTIBODY WAS INTRATHECALLY ADMINISTRATED AT DAY 2 POST-INJURY. CONSISTENT WITH BEHAVIORAL RESULTS, WESTERN BLOT ANALYSIS SHOWED THAT THE EXPRESSION LEVELS OF BDNF PROTEIN IN THE SPINAL DORSAL HORN WERE MARKEDLY INDUCED DURING EARLY STAGE POST-INJURY. MOREOVER, THE MAXIMAL INCREASE IN BDNF MRNA EXPRESSION IN THE DRG WAS OBSERVED AT DAY 1 POST-INJURY, AND SIGNIFICANTLY ELEVATED LEVELS WERE SUSTAINED FOR AT LEAST 14 DAYS. FOUR OF FIVE BDNF MRNA TRANSCRIPTS WERE UP-REGULATED AFTER NERVE INJURY, AND THE MOST INDUCIBLE TRANSCRIPT WAS EXON I. USING A CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAY, WE FOUND THAT NERVE INJURY PROMOTES HISTONE H3 AND H4 ACETYLATION, TRANSCRIPTIONALLY ACTIVE MODIFICATIONS, AT BDNF PROMOTER I AT DAY 1 POST-INJURY, AND THE LEVELS OF HISTONE ACETYLATION REMAIN ELEVATED FOR AT LEAST 7 DAYS. TAKEN TOGETHER, OUR FINDINGS SUGGEST THAT AN INITIAL INCREASE IN BDNF EXON I EXPRESSION CONTROLLED BY EPIGENETIC MECHANISMS MIGHT HAVE A CRUCIAL ROLE IN THE DEVELOPMENT OF NEUROPATHIC PAIN. 2013 17 5714 37 SIRT3 OVEREXPRESSION AND EPIGENETIC SILENCING OF CATALASE REGULATE ROS ACCUMULATION IN CLL CELLS ACTIVATING AXL SIGNALING AXIS. MITOCHONDRIAL METABOLISM IS THE KEY SOURCE FOR ABUNDANT ROS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS. HERE, WE DETECTED SIGNIFICANTLY LOWER SUPEROXIDE ANION (O(2)(-)) LEVELS WITH INCREASED ACCUMULATION OF HYDROGEN PEROXIDE (H(2)O(2)) IN CLL CELLS VS. NORMAL B-CELLS. FURTHER ANALYSIS INDICATED THAT MITOCHONDRIAL SUPEROXIDE DISMUTASE (SOD)2, WHICH CONVERTS O(2)(-) INTO H(2)O(2) REMAINED DEACETYLATED IN CLL CELLS DUE TO SIRT3 OVEREXPRESSION RESULTING ITS CONSTITUTIVE ACTIVATION. IN ADDITION, CATALASE EXPRESSION WAS ALSO REDUCED IN CLL CELLS SUGGESTING IMPAIRMENT OF H(2)O(2)-CONVERSION INTO WATER AND O(2) WHICH MAY CAUSE H(2)O(2)-ACCUMULATION. IMPORTANTLY, WE IDENTIFIED TWO CPG-ISLANDS IN THE CATALASE PROMOTER AND DISCOVERED THAT WHILE THE DISTAL CPG-ISLAND (-3619 TO -3765) REMAINED METHYLATED IN BOTH NORMAL B-CELLS AND CLL CELLS, VARIABLE DEGREES OF METHYLATION WERE DISCERNIBLE IN THE PROXIMAL CPG-ISLAND (-174 TO -332) ONLY IN CLL CELLS. FINALLY, TREATMENT OF CLL CELLS WITH A DEMETHYLATING AGENT INCREASED CATALASE MRNA LEVELS. FUNCTIONALLY, ROS ACCUMULATION IN CLL CELLS ACTIVATED THE AXL SURVIVAL AXIS WHILE UPREGULATED SIRT3, SUGGESTING THAT CLL CELLS RAPIDLY REMOVE HIGHLY REACTIVE O(2)(-) TO AVOID ITS CYTOTOXIC EFFECT BUT MAINTAIN INCREASED H(2)O(2)-LEVEL TO PROMOTE CELL SURVIVAL. THEREFORE, ABROGATION OF ABERRANTLY ACTIVATED CELL SURVIVAL PATHWAYS USING ANTIOXIDANTS CAN BE AN EFFECTIVE INTERVENTION IN CLL THERAPY IN COMBINATION WITH CONVENTIONAL AGENTS. 2021 18 4236 35 METHYLATION OF THE TYROSINE HYDROXYLASE GENE IS DYSREGULATED BY COCAINE DEPENDENCE IN THE HUMAN STRIATUM. COCAINE DEPENDENCE IS A CHRONIC, RELAPSING DISORDER CAUSED BY LASTING CHANGES IN THE BRAIN. ANIMAL STUDIES HAVE IDENTIFIED COCAINE-RELATED ALTERATIONS IN STRIATAL DNA METHYLATION; HOWEVER, IT IS UNCLEAR HOW METHYLATION IS RELATED TO COCAINE DEPENDENCE IN HUMANS. WE GENERATED METHYLOMIC PROFILES OF THE NUCLEUS ACCUMBENS USING HUMAN POSTMORTEM BRAINS FROM A COHORT OF INDIVIDUALS WITH COCAINE DEPENDENCE AND HEALTHY CONTROLS (N = 25 PER GROUP). WE FOUND HYPERMETHYLATION IN A CLUSTER OF CPGS WITHIN THE GENE BODY OF TYROSINE HYDROXYLASE (TH), CONTAINING A PUTATIVE BINDING SITE FOR THE EARLY GROWTH RESPONSE 1 (EGR1) TRANSCRIPTION FACTOR, WHICH IS HYPERMETHYLATED IN THE CAUDATE NUCLEUS OF COCAINE-DEPENDENT INDIVIDUALS. WE REPLICATED THIS FINDING AND FOUND IT TO BE SPECIFIC TO STRIATAL NEURONAL NUCLEI. FURTHERMORE, THIS LOCUS DEMONSTRATES ENHANCER ACTIVITY WHICH IS ATTENUATED BY METHYLATION AND ENHANCED BY EGR1 OVEREXPRESSION. THESE RESULTS SUGGEST THAT COCAINE DEPENDENCE ALTERS THE EPIGENETIC REGULATION OF DOPAMINERGIC SIGNALING GENES. 2021 19 101 35 A RAT METHYL-SEQ PLATFORM TO IDENTIFY EPIGENETIC CHANGES ASSOCIATED WITH STRESS EXPOSURE. AS GENOMES OF A WIDER VARIETY OF ANIMALS BECOME AVAILABLE, THERE IS AN INCREASING NEED FOR TOOLS THAT CAN CAPTURE DYNAMIC EPIGENETIC CHANGES IN THESE ANIMAL MODELS. THE RAT IS ONE PARTICULAR MODEL ANIMAL WHERE AN EPIGENETIC TOOL CAN COMPLEMENT MANY PHARMACOLOGICAL AND BEHAVIORAL STUDIES TO PROVIDE INSIGHTFUL MECHANISTIC INFORMATION. TO THIS END, WE ADAPTED THE SURESELECT TARGET CAPTURE SYSTEM (REFERRED TO AS METHYL-SEQ) FOR THE RAT, WHICH CAN ASSESS DNA METHYLATION LEVELS ACROSS THE RAT GENOME. THE RAT DESIGN TARGETED PROMOTERS, CPG ISLANDS, ISLAND SHORES, AND GC-RICH REGIONS FROM ALL REFSEQ GENES. TO IMPLEMENT THE PLATFORM ON A RAT EXPERIMENT, MALE SPRAGUE DAWLEY RATS WERE EXPOSED TO CHRONIC VARIABLE STRESS FOR 3 WEEKS, AFTER WHICH BLOOD SAMPLES WERE COLLECTED FOR GENOMIC DNA EXTRACTION. METHYL-SEQ LIBRARIES WERE CONSTRUCTED FROM THE RAT DNA SAMPLES BY SHEARING, ADAPTER LIGATION, TARGET ENRICHMENT, BISULFITE CONVERSION, AND MULTIPLEXING. LIBRARIES WERE SEQUENCED ON A NEXT-GENERATION SEQUENCING PLATFORM AND THE SEQUENCED READS WERE ANALYZED TO IDENTIFY DMRS BETWEEN DNA OF STRESSED AND UNSTRESSED RATS. TOP CANDIDATE DMRS WERE INDEPENDENTLY VALIDATED BY BISULFITE PYROSEQUENCING TO CONFIRM THE ROBUSTNESS OF THE PLATFORM. RESULTS DEMONSTRATE THAT THE RAT METHYL-SEQ PLATFORM IS A USEFUL EPIGENETIC TOOL THAT CAN CAPTURE METHYLATION CHANGES INDUCED BY EXPOSURE TO STRESS. 2018 20 6767 25 ZNF382 CONTROLS MOUSE NEUROPATHIC PAIN VIA SILENCER-BASED EPIGENETIC INHIBITION OF CXCL13 IN DRG NEURONS. NERVE INJURY-INDUCED CHANGES OF GENE EXPRESSION IN DORSAL ROOT GANGLION (DRG) ARE CRITICAL FOR NEUROPATHIC PAIN GENESIS. HOWEVER, HOW THESE CHANGES OCCUR REMAINS ELUSIVE. HERE WE REPORT THE DOWN-REGULATION OF ZINC FINGER PROTEIN 382 (ZNF382) IN INJURED DRG NEURONS AFTER NERVE INJURY. RESCUING THIS DOWN-REGULATION ATTENUATES NOCICEPTIVE HYPERSENSITIVITY. CONVERSELY, MIMICKING THIS DOWN-REGULATION PRODUCES NEUROPATHIC PAIN SYMPTOMS, WHICH ARE ALLEVIATED BY C-X-C MOTIF CHEMOKINE 13 (CXCL13) KNOCKDOWN OR ITS RECEPTOR CXCR5 KNOCKOUT. MECHANISTICALLY, AN IDENTIFIED CIS-ACTING SILENCER AT DISTAL UPSTREAM OF THE CXCL13 PROMOTER SUPPRESSES CXCL13 TRANSCRIPTION VIA BINDING TO ZNF382. BLOCKING THIS BINDING OR GENETICALLY DELETING THIS SILENCER ABOLISHES THE ZNF382 SUPPRESSION ON CXCL13 TRANSCRIPTION AND IMPAIRS ZNF382-INDUCED ANTINOCICEPTION. MOREOVER, ZNF382 DOWN-REGULATION DISRUPTS THE REPRESSIVE EPIGENETIC COMPLEX CONTAINING HISTONE DEACETYLASE 1 AND SET DOMAIN BIFURCATED 1 AT THE SILENCER-PROMOTER LOOP, RESULTING IN CXCL13 TRANSCRIPTIONAL ACTIVATION. THUS, ZNF382 DOWN-REGULATION IS REQUIRED FOR NEUROPATHIC PAIN LIKELY THROUGH SILENCER-BASED EPIGENETIC DISINHIBITION OF CXCL13, A KEY NEUROPATHIC PAIN PLAYER, IN DRG NEURONS. 2021